drugset

drugset / Trial / NCT04692766

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

NCT04692766 ↗

Phase 2/3 Completed 20 enrolled R-Pharm International, LLC Center of Pharmaceutical Analytics LLC · collab Data Management 365 · collab Unimed Laboratories · collab

RandomizedSequentialTriple-blindTreatment

Summary

The goal of this study was to evaluate the Efficacy and Safety of RPH-104 Treatment in patients in comparison to placebo with Idiopathic Recurrent Pericarditis

Timeline

Start: 2020-02-12
Primary completion: 2022-01-24
Completion: 2022-03-22

Publications

Myachikova VY, Maslyanskiy AL, Moiseeva OM, Vinogradova OV, Gleykina EV, Lavrovsky Y, Abbate A, Grishin SA, Egorova AN, Schedrova ML, Samsonov MY. Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. J Am Coll Cardiol. 2023 Jul 4;82(1):30-40. doi: 10.1016/j.jacc.2023.04.046.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Goflikicept	Monoclonal antibody	80 mg	Subcutaneous

Indications